I am a pulmonary & critical care physician-scientist whose interests focus on the intersection between clinical risk-prediction models and genomic markers to improve pulmonary fibrosis outcomes.
Pulmonary fibrosis is a destructive interstitial lung disease characterized by profound scarring. In severe pulmonary fibrosis, death generally ensues within three to five years. Recent genomic advances have identified factors that influence heterogeneity and prognosis in pulmonary fibrosis. However, healthcare disparities and the exclusion of major racial groups from these genetic studies limits the generalizability of their findings. My work leverages advanced statistical techniques to improve the delivery of high-quality care in patients with fibrotic lung diseases. Much of my research is aimed at identifying improved practical strategies to optimize pharmacotherapy in patients with pulmonary fibrosis.
The main thrust of my work is currently on utilizing genetic data from diverse races to improve clinical decision-making and outcomes for all patients with pulmonary fibrosis.
Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement.
Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement. Eur Respir J. 2025 Dec; 66(6).
PMID: 40774805
Transcriptomic Profiling of Long COVID-19 in Patients with Interstitial Lung Disease Reveals Dysregulation of Mitochondrial Oxidative Phosphorylation.
Transcriptomic Profiling of Long COVID-19 in Patients with Interstitial Lung Disease Reveals Dysregulation of Mitochondrial Oxidative Phosphorylation. Am J Respir Cell Mol Biol. 2025 Oct; 73(4):634-637.
PMID: 40305670
Genetics of interstitial lung diseases: a state-of-the-art review.
Genetics of interstitial lung diseases: a state-of-the-art review. Eur Respir J. 2025 Sep; 66(3).
PMID: 40841141
Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease.
Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Am J Respir Crit Care Med. 2025 Aug; 211(8):1452-1462.
PMID: 40208180
Surgical lung biopsy analyses differ by race and ethnicity in interstitial lung disease.
Surgical lung biopsy analyses differ by race and ethnicity in interstitial lung disease. ERJ Open Res. 2025 Jul; 11(4).
PMID: 40630386
Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.
Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement. Am J Respir Crit Care Med. 2025 Jul; 211(7):1132-1155.
PMID: 40387336
Triaging acute chest syndrome clinical decision-making using bedside SaO2/FiO2 ratio.
Triaging acute chest syndrome clinical decision-making using bedside SaO2/FiO2 ratio. Blood Adv. 2025 Jun 24; 9(12):2970-2979.
PMID: 40179390
Accelerated epigenetic ageing worsens survival and mediates environmental stressors in fibrotic interstitial lung disease.
Accelerated epigenetic ageing worsens survival and mediates environmental stressors in fibrotic interstitial lung disease. Eur Respir J. 2025 Jun; 65(6).
PMID: 39884761
Elevated blood anandamide levels in acute COVID-19 pneumonia with respiratory failure.
Elevated blood anandamide levels in acute COVID-19 pneumonia with respiratory failure. Am J Med Sci. 2025 Sep; 370(3):271-277.
PMID: 40480300
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation.
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation. Lancet Respir Med. 2025 Jun; 13(6):495-504.
PMID: 40311650